Edward Gomperts is emeritus clinical professor of pediatrics and pathology at the University of Southern California (USC), an attending physician at Children’s Hospital, Los Angeles (CHLA) and executive chairman of Hillhurst Biopharmaceuticals Inc.  He has spent more than 15 years in the pharmaceutical industry, where he led the translational development of biopharmaceutical products. He served as director of clinical research at CHLA and as co-director of the CTSI at CHLA/USC. Dr. Gomperts has experience as a medical monitor regarding product licensure activities and a member of DMC’s. His clinical and academic efforts became even more relevant with the advent of the HIV tragedy that impacted more than 100 of my patients with hemophilia. The experience of developing better therapeutics for hemophilia led him to seek therapeutic treatments for other serious conditions. Hillhurst aims to develop a safe, effective, oral administered carbon monoxide-based therapeutic to treat Parkinson’s disease.